多发性骨髓瘤患者应用含硼替佐米方案对循环中微颗粒水平及凝血功能的影响

Influence of Borotezomib regimen on circulating micro-particle level and coagulation function in patients with multiple myeloma

目的观察多发性骨髓瘤患者应用含硼替佐米方案对循环中微颗粒水平及凝血功能的影响,探索最佳治疗措施,裨益临床。方法选择2013年4月—2019年4月本院收治的80例多发性骨髓瘤患者作为研究对象,均接受含硼替佐米方案诱导化疗,分别在治疗前(T 0)和含硼替佐米方案诱导治疗后第3个疗程(T 1),采集患者的外周血样本,使用全自动血凝分析仪测定凝血功能相关指标,主要包括PT、APTT、Fbg、D-D、TT、FVⅢ、protein C、protein S、AT-Ⅲ和PAI,同时检测循环中微颗粒水平。结果凝血指标而言,与T 0时间段比较,T 1时间段的APTT、D-D、PAI降低明显,而protein C、protein S、AT-Ⅲ则升高明显,差异具统计学意义(P<0.05)。循环中微颗粒水平检测结果显示,与T 0时间段比较,T 1时间段的TMPs降低明显,差异具统计学意义(P<0.05)。结论多发性骨髓瘤患者中应用含硼替佐米方案可降低患者循环中微颗粒水平,改善凝血功能。

Objective To observe the effect of Borotezomib regimen on circulating micro-particle level and coagulation function in patients with multiple myeloma,and to explore the best treatment measures,which is beneficial to clinical practice.Methods The patients those who received the Borotezomib regimen for the chemotherapy out of the 80 patients with multiple myeloma admitted to our hospital from April 2013 to April 2019 were included in the study.Before treatment(T 0)and the third course of treatment(T 1)after induction therapy with Borotezomib,the peripheral blood samples were collected and the relevant indexes of coagulation function were determined by automatic hemagglutination analyzer.It mainly includes PT,APTT,Fbg,D-D,TT,FVⅢ,protein C,protein S,AT-Ⅲand PAI.At the same time,the level of micro-particles in the cycle was detected.Results Compared with T0 time period,APTT,D-D,PAI and TMPs decreased significantly,while protein C,protein S and AT-Ⅲincreased significantly(P<005).Conclusions Borotezomib regimen could improve the level of micro-particles in circulation and regulate the function of blood coagulation in patients with multiple myeloma.